{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:11:38Z","timestamp":1791515498418,"version":"4.3.4"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["NS098088"],"award-info":[{"award-number":["NS098088"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["603852"],"award-info":[{"award-number":["603852"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004952","name":"Minnesota Department of Agriculture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004952","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007721","name":"Cure SMA","doi-asserted-by":"publisher","award":["F31 NS106753"],"award-info":[{"award-number":["F31 NS106753"]}],"id":[{"id":"10.13039\/100007721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007721","name":"Cure SMA","doi-asserted-by":"publisher","award":["MER2021"],"award-info":[{"award-number":["MER2021"]}],"id":[{"id":"10.13039\/100007721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS098088"],"award-info":[{"award-number":["NS098088"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS090644"],"award-info":[{"award-number":["NS090644"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jbc.2021.100302","type":"journal-article","created":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T22:44:13Z","timestamp":1610923453000},"page":"100302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs"],"prefix":"10.1016","volume":"296","author":[{"given":"Kristine S.","family":"Ojala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott P.","family":"Ginebaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Covarrubias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2005-9726","authenticated-orcid":false,"given":"Stephen D.","family":"Meriney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2021.100302_bib1","first-page":"612","article-title":"Defect of neuromuscular conduction associated with malignant neoplasms","volume":"187","author":"Lambert","year":"1956","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.jbc.2021.100302_bib2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1113\/jphysiol.1983.sp014943","article-title":"Antibodies to motor nerve terminals: An electrophysiological study of a human myasthenic syndrome transferred to mouse","volume":"344","author":"Lang","year":"1983","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.jbc.2021.100302_bib3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/0166-2236(89)90109-4","article-title":"Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder","volume":"12","author":"Vincent","year":"1989","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jbc.2021.100302_bib4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ana.410240412","article-title":"Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation","volume":"24","author":"Nagel","year":"1988","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jbc.2021.100302_bib5","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ana.410400510","article-title":"Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma","volume":"40","author":"Meriney","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jbc.2021.100302_bib6","doi-asserted-by":"crossref","first-page":"10559","DOI":"10.1523\/JNEUROSCI.4629-12.2013","article-title":"Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome","volume":"33","author":"Tarr","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.jbc.2021.100302_bib7","article-title":"FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder","year":"2018","journal-title":"Fed. Drug Adm."},{"key":"10.1016\/j.jbc.2021.100302_bib8","article-title":"FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder","year":"2019","journal-title":"Fed. Drug Adm."},{"key":"10.1016\/j.jbc.2021.100302_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1060028019864574","article-title":"Amifampridine for the Management of Lambert-Eaton myasthenic syndrome: A new take on an old drug","volume":"54","author":"Yoon","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jbc.2021.100302_bib10","first-page":"239","article-title":"Drug approved for rare muscle weakening syndrome","volume":"321","author":"Voelker","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jbc.2021.100302_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mus.24921","article-title":"Myasthenia gravis Lambert-Eaton overlap syndrome","volume":"53","author":"Oh","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jbc.2021.100302_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1212\/CPJ.0000000000000321","article-title":"Aminopyridines for the treatment of neurologic disorders","volume":"7","author":"Strupp","year":"2017","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.jbc.2021.100302_bib13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/mus.26052","article-title":"3,4-Diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia","volume":"57","author":"Sanders","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jbc.2021.100302_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/CND.0000000000000239","article-title":"Amifampridine phosphate (Firdapse) is effective in a confirmatory phase 3 clinical trial in LEMS","volume":"20","author":"Shieh","year":"2019","journal-title":"J.\u00a0Clin. Neuromuscul. Dis."},{"key":"10.1016\/j.jbc.2021.100302_bib15","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1586\/eci.10.57","article-title":"3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome","volume":"6","author":"Wirtz","year":"2010","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.jbc.2021.100302_bib16","first-page":"341","article-title":"Update on treatment options for Lambert\u2013Eaton myasthenic syndrome: Focus on use of amifampridine","volume":"7","author":"Lindquist","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jbc.2021.100302_bib17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1749-6632.1998.tb11022.x","article-title":"3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS)","volume":"841","author":"Sanders","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jbc.2021.100302_bib18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":"Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: A randomized, double-blind, placebo-controlled, crossover study","volume":"86","author":"Wirtz","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jbc.2021.100302_bib19","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.clinthera.2015.05.498","article-title":"Effects of food intake on the relative bioavailability of amifampridine phosphate salt in healthy adults","volume":"37","author":"Haroldsen","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jbc.2021.100302_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.99","article-title":"Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate","volume":"3","author":"Haroldsen","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.jbc.2021.100302_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/psp4.12218","article-title":"Population pharmacokinetics\/pharmacodynamics of 3,4-diaminopyridine free base in patients with Lambert-Eaton myasthenia","volume":"6","author":"Thakkar","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.jbc.2021.100302_bib22","doi-asserted-by":"crossref","first-page":"674","DOI":"10.5414\/CP202133","article-title":"Pharmacokinetics and safety of 3,4-diaminopyridine base in healthy Japanese volunteers","volume":"53","author":"Ishida","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jbc.2021.100302_bib23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.nmd.2003.11.004","article-title":"Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine","volume":"14","author":"Banwell","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jbc.2021.100302_bib24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.clineuro.2015.01.010","article-title":"Clinical and neurophysiological response to pharmacological treatment of DOK7 congenital myasthenia in an older patient","volume":"130","author":"Witting","year":"2015","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jbc.2021.100302_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.nmd.2015.10.013","article-title":"Long-term follow-up in patients with congenital myasthenic syndrome due to RAPSN mutations","volume":"26","author":"Natera-de Benito","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jbc.2021.100302_bib26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.nmd.2016.08.005","article-title":"Phenotypic heterogeneity in two large Roma families with a congenital myasthenic syndrome due to CHRNE 1267delG mutation. A long-term follow-up","volume":"26","author":"Natera-de Benito","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.jbc.2021.100302_bib27","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/jnnp-2016-313163","article-title":"Clinical features of the myasthenic syndrome arising from mutations in GMPPB","volume":"87","author":"Rodr\u00edguez Cruz","year":"2016","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jbc.2021.100302_bib28","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/brain\/awz107","article-title":"The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations","volume":"142","author":"Rodr\u00edguez Cruz","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jbc.2021.100302_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/2050312118819013","article-title":"Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: A phase IIb, randomized, double-blind, placebo-controlled, double crossover study","volume":"6","author":"Bonanno","year":"2018","journal-title":"SAGE Open Med."},{"key":"10.1016\/j.jbc.2021.100302_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11940-011-0154-5","article-title":"Treatment of nystagmus","volume":"14","author":"Thurtell","year":"2012","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.jbc.2021.100302_bib31","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/archneur.1994.00540150090022","article-title":"4-Aminopyridine in the treatment of patients with multiple sclerosis: Long-term efficacy and safety","volume":"51","author":"Polman","year":"1994","journal-title":"Arch. Neurol."},{"issue":"Pt 5","key":"10.1016\/j.jbc.2021.100302_bib32","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/brain\/121.5.967","article-title":"An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis","volume":"121","author":"Sheean","year":"1998","journal-title":"Brain"},{"key":"10.1016\/j.jbc.2021.100302_bib33","first-page":"937","article-title":"3,4-Diaminopyridine safety in clinical practice: An observational, retrospective cohort study","volume":"257","author":"Flet","year":"2010","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.jbc.2021.100302_bib34","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1212\/01.WNL.0000129263.14219.A8","article-title":"Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine","volume":"62","author":"Mainero","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jbc.2021.100302_bib35","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1111\/j.1460-9568.2004.03730.x","article-title":"Kv3 voltage-gated potassium channels regulate neurotransmitter release from mouse motor nerve terminals","volume":"20","author":"Brooke","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.jbc.2021.100302_bib36","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1113\/jphysiol.1967.sp008367","article-title":"Co-operative action a calcium ions in transmitter release at the neuromuscular junction","volume":"193","author":"Dodge","year":"1967","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.jbc.2021.100302_bib37","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/S0026-895X(25)10596-8","article-title":"Aminopyridine block of Kv1.1 potassium channels expressed in mammalian cells and Xenopus oocytes","volume":"45","author":"Castle","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jbc.2021.100302_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0014-5793(89)81488-7","article-title":"Potassium channels from NG108-15 neuroblastoma-glioma hybrid cells. Primary structure and functional expression from cDNAs","volume":"259","author":"Yokoyama","year":"1989","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jbc.2021.100302_bib39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1113\/jphysiol.1994.sp020183","article-title":"On the mechanism of 4-aminopyridine action on the cloned mouse brain potassium channel mKv1.1","volume":"477","author":"Stephens","year":"1994","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.jbc.2021.100302_bib40","doi-asserted-by":"crossref","first-page":"e6168","DOI":"10.1371\/journal.pone.0006168","article-title":"Characterization of voltage-gated potassium channels in human neural progenitor cells","volume":"4","author":"Schaarschmidt","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2021.100302_bib41","doi-asserted-by":"crossref","first-page":"36453","DOI":"10.1074\/jbc.M109.075523","article-title":"Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel \u03b2 subunit","volume":"284","author":"Wu","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2021.100302_bib42","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0026-895X(25)10594-4","article-title":"Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines","volume":"45","author":"Grissmer","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jbc.2021.100302_bib43","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1073\/pnas.88.9.3932","article-title":"Alternative splicing contributes to K+ channel diversity in the mammalian central nervous system","volume":"88","author":"Luneau","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.jbc.2021.100302_bib44","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1523\/JNEUROSCI.3212-17.2018","article-title":"Regulation of nociceptive glutamatergic signaling by presynaptic Kv3.4 channels in the rat spinal dorsal horn","volume":"38","author":"Muqeem","year":"2018","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.jbc.2021.100302_bib45","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/j.1460-2075.1992.tb05312.x","article-title":"Characterization of a shaw-related potassium channel family in rat brain","volume":"11","author":"Rettig","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.jbc.2021.100302_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1098\/rspb.1992.0036","article-title":"Cloning of ShIII (shaw-like) cDNAs encoding a novel high-voltage-activating, TEA-sensitive, type-A K+ channel","volume":"248","author":"Vega-Saenz de Miera","year":"1992","journal-title":"Proc. Biol. Sci."},{"key":"10.1016\/j.jbc.2021.100302_bib47","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1085\/jgp.102.5.797","article-title":"Gating-dependent mechanism of 4-aminopyridine block in two related potassium channels","volume":"102","author":"Kirsch","year":"1993","journal-title":"J.\u00a0Gen. Physiol."},{"key":"10.1016\/j.jbc.2021.100302_bib48","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0006-8993(84)90875-8","article-title":"Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats","volume":"304","author":"Lemeignan","year":"1984","journal-title":"Brain Res."},{"key":"10.1016\/j.jbc.2021.100302_bib49","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/21678707.2014.887464","article-title":"3,4-Diaminopyridine (amifampridine) for the treatment of Lambert\u2013Eaton myasthenic syndrome","volume":"2","author":"Lindquist","year":"2014","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.jbc.2021.100302_bib50","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0006-3495(78)85503-9","article-title":"3,4-diaminopyridine. A potent new potassium channel blocker","volume":"22","author":"Kirsch","year":"1978","journal-title":"Biophys. J."},{"key":"10.1016\/j.jbc.2021.100302_bib51","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/mol.114.095505","article-title":"Potentiation of high voltage-activated calcium channels by 4-aminopyridine depends on subunit composition","volume":"86","author":"Li","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jbc.2021.100302_bib52","doi-asserted-by":"crossref","first-page":"16100","DOI":"10.1074\/jbc.L118.005425","article-title":"Reported direct aminopyridine effects on voltage-gated calcium channels is a high-dose pharmacological off-target effect of no clinical relevance","volume":"293","author":"Meriney","year":"2018","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2021.100302_bib53","doi-asserted-by":"crossref","first-page":"16101","DOI":"10.1074\/jbc.RL118.005655","article-title":"Reply to Meriney and Lacomis: Comment on direct aminopyridine effects on voltage-gated Ca2+ channels","volume":"293","author":"Wu","year":"2018","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2021.100302_bib54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1023\/A:1021985521748","article-title":"Physical link and functional coupling of presynaptic calcium channels and the synaptic vesicle docking\/fusion machinery","volume":"30","author":"Sheng","year":"1998","journal-title":"J.\u00a0Bioenerg. Biomembr."},{"key":"10.1016\/j.jbc.2021.100302_bib55","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1749-6632.1999.tb11284.x","article-title":"Interactions of presynaptic Ca2+ channels and snare proteins in neurotransmitter release","volume":"868","author":"Catterall","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jbc.2021.100302_bib56","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1073\/pnas.262787699","article-title":"Requirement for the synaptic protein interaction site for reconstitution of synaptic transmission by P\/Q-type calcium channels","volume":"100","author":"Mochida","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2021.100302_bib57","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0006-8993(87)90599-3","article-title":"Bay K 8644 increases release of acetylcholine at the murine neuromuscular junction","volume":"419","author":"Atchison","year":"1987","journal-title":"Brain Res."},{"key":"10.1016\/j.jbc.2021.100302_bib58","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0306-4522(89)90366-7","article-title":"Effects of Bay K 8644 on spontaneous and evoked transmitter release at the mouse neuromuscular junction","volume":"30","author":"Pancrazio","year":"1989","journal-title":"Neuroscience"},{"key":"10.1016\/j.jbc.2021.100302_bib59","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0022-3565(25)20860-6","article-title":"Dihydropyridine-sensitive and -insensitive components of acetylcholine release from rat motor nerve terminals","volume":"251","author":"Atchison","year":"1989","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jbc.2021.100302_bib60","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/0968768021000035087","article-title":"Calcium channels involved in neurotransmitter release at adult, neonatal and P\/Q-type deficient neuromuscular junctions (Review)","volume":"19","author":"Urbano","year":"2002","journal-title":"Mol. Membr. Biol."},{"key":"10.1016\/j.jbc.2021.100302_bib61","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1113\/jphysiol.2002.021048","article-title":"Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission","volume":"543","author":"Flink","year":"2002","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.jbc.2021.100302_bib62","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1152\/jn.1998.80.3.1056","article-title":"Passive transfer of Lambert-Eaton myasthenic syndrome induces dihydropyridine sensitivity of ICa in mouse motor nerve terminals","volume":"80","author":"Xu","year":"1998","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.jbc.2021.100302_bib63","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1021\/jacs.5b06644","article-title":"A\u00a0photostable silicon rhodamine platform for optical voltage sensing","volume":"137","author":"Huang","year":"2015","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.jbc.2021.100302_bib64","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1523\/JNEUROSCI.2415-19.2020","article-title":"The frog motor nerve terminal has very brief action potentials and three electrical regions predicted to differentially control transmitter release","volume":"40","author":"Ginebaugh","year":"2020","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.jbc.2021.100302_bib65","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1113\/jphysiol.1981.sp013586","article-title":"Non-linear summation of end-plate potentials in the frog and mouse","volume":"311","author":"McLachlan","year":"1981","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.jbc.2021.100302_bib66","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0304-3940(93)90745-7","article-title":"Use of mu-conotoxin GIIIA for the study of synaptic transmission at the frog neuromuscular junction","volume":"157","author":"Sosa","year":"1993","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jbc.2021.100302_bib67","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1113\/jphysiol.2014.276493","article-title":"Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist","volume":"592","author":"Tarr","year":"2014","journal-title":"J.\u00a0Physiol."},{"key":"10.1016\/j.jbc.2021.100302_bib68","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/mus.25208","article-title":"Effect of 3,4-diaminopyridine at the murine neuromuscular junction","volume":"55","author":"Fiona","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jbc.2021.100302_bib69","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0014-2999(80)90378-7","article-title":"Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes","volume":"6","author":"Molg\u00f3","year":"1980","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jbc.2021.100302_bib70","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1085\/jgp.108.3.207","article-title":"Molecular identification of SqKv1A. A candidate for the delayed rectifier K channel in squid giant axon","volume":"108","author":"Rosenthal","year":"1996","journal-title":"J.\u00a0Gen. Physiol."},{"key":"10.1016\/j.jbc.2021.100302_bib71","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1523\/JNEUROSCI.0972-11.2011","article-title":"Sparse but highly efficient Kv3 outpace BKCa channels in action potential repolarization at hippocampal mossy fiber boutons","volume":"31","author":"Alle","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.jbc.2021.100302_bib72","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.celrep.2017.01.068","article-title":"Rapid state-dependent alteration in Kv3 channel availability drives flexible synaptic signaling dependent on somatic subthreshold depolarization","volume":"18","author":"Rowan","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.jbc.2021.100302_bib73","doi-asserted-by":"crossref","first-page":"6611","DOI":"10.1523\/JNEUROSCI.4208-13.2014","article-title":"Distinct Kv channel subtypes contribute to differences in spike signaling properties in the axon initial segment and presynaptic boutons of cerebellar interneurons","volume":"34","author":"Rowan","year":"2014","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.jbc.2021.100302_bib74","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.neuron.2016.05.035","article-title":"Synapse-level determination of action potential duration by K(+) channel clustering in axons","volume":"91","author":"Rowan","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.jbc.2021.100302_bib75","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1152\/physrev.00002.2017","article-title":"Kv3 channels: Enablers of rapid firing, neurotransmitter release, and neuronal endurance","volume":"97","author":"Kaczmarek","year":"2017","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jbc.2021.100302_bib76","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3389\/fnmol.2018.00253","article-title":"A-type KV channels in dorsal root ganglion neurons: Diversity, function, and dysfunction","volume":"11","author":"Zemel","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.jbc.2021.100302_bib77","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0166-2236(00)01892-0","article-title":"Kv3 channels: Voltage-gated K+ channels designed for high-frequency repetitive firing","volume":"24","author":"Rudy","year":"2001","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jbc.2021.100302_bib78","doi-asserted-by":"crossref","first-page":"11268","DOI":"10.1523\/JNEUROSCI.1394-11.2011","article-title":"Single-pixel optical fluctuation analysis of calcium channel function in active zones of motor nerve terminals","volume":"31","author":"Luo","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.jbc.2021.100302_bib79","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1152\/jn.00879.2014","article-title":"Transmitter release is evoked with low probability predominately by calcium flux through single channel openings at the frog neuromuscular junction","volume":"113","author":"Luo","year":"2015","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.jbc.2021.100302_bib80","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.tins.2012.09.009","article-title":"Are unreliable release mechanisms conserved from NMJ to CNS?","volume":"36","author":"Tarr","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jbc.2021.100302_bib81","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.neuropharm.2017.12.022","article-title":"New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease","volume":"131","author":"Wu","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jbc.2021.100302_bib82","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fncel.2016.00276","article-title":"A\u00a0novel striated muscle-specific myosin-blocking drug for the study of neuromuscular physiology","volume":"10","author":"Heredia","year":"2016","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.jbc.2021.100302_bib83","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1073\/pnas.1106377109","article-title":"Spatial organization of the extracellular matrix regulates cell-cell junction positioning","volume":"109","author":"Tseng","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.jbc.2021.100302_bib84","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1039\/c0lc00641f","article-title":"A\u00a0new micropatterning method of soft substrates reveals that different tumorigenic signals can promote or reduce cell contraction levels","volume":"11","author":"Tseng","year":"2011","journal-title":"Lab. Chip"},{"key":"10.1016\/j.jbc.2021.100302_bib85","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1109\/TSMC.1979.4310076","article-title":"A\u00a0threshold selection method from gray-level histograms","volume":"9","author":"Otsu","year":"1979","journal-title":"IEEE Trans. Syst. Man Cybern."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925821000715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925821000715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:52:20Z","timestamp":1777409540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925821000715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":85,"alternative-id":["S0021925821000715"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2021.100302","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2021.100302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100302"}}